Levetiracetam may be an unsuitable choice for patients with PRRT2-associated self-limited infantile epilepsy.

ABSTRACT:

Introduction

Self-limited infantile epilepsy (SeLIE) is a benign epilepsy. Previous studies have shown that monotherapy with most antiseizure medications can effectively relieve seizures in patients with SeLIE, but the efficacy of levetiracetam has not been investigated.

Objective

This study aimed to investigate the efficacy of levetiracetam in the treatment of SeLIE patients with PRRT2 mutations.

Methods

The clinical data of 39 SeLIE patients (21 males and 18 females, aged 4.79 ± 1.60 months) with pathogenic variants in PRRT2 or 16p11.2 microdeletion were retrospectively analyzed. Based on the use of initial antiseizure medication (ASM), the patients were classified into two groups: Levetiracetam group (LEG) and Other ASMs group (OAG). The difference of efficacy betw

SUBMITTER: Tian Y 

PROVIDER: S-EPMC10601096 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature